ArticleFrontiers in medicine2025
Endoscopic retrograde submucosal tunnel resection for cervical esophageal submucosal tumors via percutaneous gastrostomy: a conceptual approach.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Management of submucosal tumors (SMTs) or subepithelial lesions (SELs) at the cervical esophagus remains technically challenging due to limited maneuvering space and short oral mucosal length for conventional submucosal tunnel endoscopic resection (STER). We propose a novel conceptual approach-endoscopic retrograde submucosal tunnel resection (ER-STER)-which enables retrograde access to cervical esophageal SMTs through a percutaneous endoscopic gastrostomy (PG) and anal submucosal tunnel. This technique could potentially enlarge the working space and reduce manipulation near the upper esophageal sphincter (UES), while introducing uncertainties such as PEG-related morbidity, retrograde tunnel perforation, and mediastinal contamination risk. This hypothesis-generating article outlines the rationale, procedural concept, risk analysis, and a translational roadmap for ER-STER. By shifting tunnel entry to the anal side, ER-STER may address the anatomical limitations of conventional STER and reduce patient discomfort associated with proximal mucosal injury. While still theoretical, this method warrants further exploration for feasibility, safety, and clinical utility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.